| SC 13G/A | 2024-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Ultragenyx Pharmaceutical Inc. | 3,453,460 | 4.2% | EDGAR |
| SC 13G/A | 2024-02-14 | RTW INVESTMENTS, LP | Ultragenyx Pharmaceutical Inc. | 6,887,086 | 8.4% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Ultragenyx Pharmaceutical Inc. | 8,673,432 | 10.6% | EDGAR |
| SC 13G | 2024-02-13 | SANDS CAPITAL MANAGEMENT, LLC | Ultragenyx Pharmaceutical Inc. | 4,118,008 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Ultragenyx Pharmaceutical Inc. | 4,415,029 | 5.4% | EDGAR |
| SC 13G/A | 2024-01-29 | BlackRock Inc. | Ultragenyx Pharmaceutical Inc. | 5,238,400 | 6.4% | EDGAR |
| SC 13G/A | 2023-09-11 | VANGUARD GROUP INC | Ultragenyx Pharmaceutical Inc. | 7,236,523 | 10.1% | EDGAR |
| SC 13G/A | 2023-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Ultragenyx Pharmaceutical Inc. | 4,096,388 | 5.8% | EDGAR |
| SC 13G | 2023-02-14 | RTW INVESTMENTS, LP | Ultragenyx Pharmaceutical Inc. | 3,966,915 | 5.7% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Ultragenyx Pharmaceutical Inc. | 6,374,230 | 9.1% | EDGAR |
| SC 13G | 2023-02-06 | WELLINGTON MANAGEMENT GROUP LLP | Ultragenyx Pharmaceutical Inc. | 5,202,684 | 7.4% | EDGAR |
| SC 13G | 2023-02-03 | BlackRock Inc. | Ultragenyx Pharmaceutical Inc. | 4,336,492 | 6.2% | EDGAR |
| SC 13G/A | 2023-01-10 | FEDERATED HERMES, INC. | Ultragenyx Pharmaceutical Inc. | 3,094,500 | 4.4% | EDGAR |
| SC 13G/A | 2022-12-09 | Capital International Investors | Ultragenyx Pharmaceutical Inc. | 1,711,517 | 2.4% | EDGAR |
| SC 13G/A | 2022-08-10 | PRICE T ROWE ASSOCIATES INC /MD/ | Ultragenyx Pharmaceutical Inc. | 5,675,998 | 8.1% | EDGAR |
| SC 13G/A | 2022-03-09 | BlackRock Inc. | Ultragenyx Pharmaceutical Inc. | 3,411,414 | 4.9% | EDGAR |
| SC 13G/A | 2022-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Ultragenyx Pharmaceutical Inc. | 11,525,089 | 16.9% | EDGAR |
| SC 13G/A | 2022-02-14 | FEDERATED HERMES, INC. | Ultragenyx Pharmaceutical Inc. | 3,986,870 | 5.8% | EDGAR |
| SC 13G/A | 2022-02-11 | Capital International Investors | Ultragenyx Pharmaceutical Inc. | 5,629,453 | 8.3% | EDGAR |
| SC 13G/A | 2022-02-10 | VANGUARD GROUP INC | Ultragenyx Pharmaceutical Inc. | 5,920,568 | 8.7% | EDGAR |